Niagen Bioscience Launches NB4168, a Proprietary NAD+ Precursor, as First Pharmaceutical Candidate for Ataxia Telangiectasia
核心洞察
Niagen Bioscience (搜索) announced the formal launch of NB4168 (搜索), its first investigational drug candidate targeting Ataxia Telangiectasia (搜索) (A-T), a rare pediatric genetic disease with no FDA-approved therapies.
NB4168 (搜索) is a proprietary, patented derivative of nicotinamide riboside (NR) designed to deliver significantly increased bioavailability and a differentiated pharmacokinetic profile compared to NR chloride.
The program builds on two independent published clinical studies of NR in A-T that showed statistically significant results, along with preclinical evidence in DNA-repair and accelerated-aging disorders.
Niagen Bioscience (搜索), Inc. (NASDAQ: NAGE) announced on July 8, 2026, the formal launch of NB4168 (搜索), the first drug candidate from its wholly owned subsidiary NAD Pharmaceuticals Corp. (搜索), marking the company's strategic expansion from consumer cellular-health products into regulated pharmaceutical development. NB4168, a proprietary derivative of the NAD+ precursor nicotinamide riboside (NR), enters development with Ataxia Telangiectasia (搜索) (A-T) as its initial indication — a rare, progressive genetic disease for which no FDA-approved therapies currently exist.
"NB4168 (搜索) is the next step in our strategy to translate Niagen Bioscience (搜索)'s NAD+ leadership into pharmaceutical development," said Rob Fried, Chief Executive Officer of Niagen Bioscience. "There are two independent, published clinical studies investigating the impact of NR on A-T, both of which have shown statistically significant results, in addition to several non-clinical studies. We believe this body of work significantly de-risks the development pathway for NB4168, which we specifically developed for therapeutic applications."
Ataxia Telangiectasia: A Rare Disease with High Unmet Need
A-T is caused by mutations in the ATM gene (搜索) and typically presents in early childhood. The disease is characterized by progressive loss of motor coordination, impaired immune function, increased susceptibility to infections, pulmonary complications, and a substantially elevated risk of cancer. As the disease progresses, many children require wheelchair assistance due to worsening neurological disability. Current treatment is largely limited to supportive care.
Epidemiological data cited by the company indicate that A-T impacts roughly 1 in 40,000 people in the United States (Riboldi et al., 2023; Tieve et al., 2015) and 1 in 150,000 people in Europe (Bhatt et al., 2015).
NB4168: A Differentiated NAD+ Precursor
NB4168 (搜索) is a distinct, proprietary molecule designed specifically for oral pharmaceutical development. It is not commercially available as a supplement or approved drug and is protected by Niagen Bioscience (搜索)'s patent portfolio, including a composition-of-matter patent. Following oral administration, NB4168 is designed to safely deliver significantly increased doses of NR to the bloodstream, where NR enters cells directly and is converted through the nicotinamide riboside kinase pathway into NAD+ — a coenzyme central to energy metabolism, DNA repair, mitochondrial function, and cellular stress responses.
In nonclinical pharmacokinetic studies conducted to date, NB4168 (搜索) has demonstrated substantially higher blood exposure to the active moiety compared with NR chloride, supporting its continued development as a more bioavailable pharmaceutical candidate.
Building on Published Clinical Evidence
The NB4168 (搜索) program is supported by a body of published research on NR in A-T. Two independent open-label clinical studies and several preclinical studies of NR chloride reported improvements in neurological measures and related biomarkers (Presterud et al., 2023; Veenhuis et al., 2021; Yang et al., 2021; Fang et al., 2016). Additionally, NR and NAD+ augmentation have been studied in other DNA-repair and accelerated-aging disorders, including Werner syndrome (搜索), Cockayne syndrome (搜索), and xeroderma pigmentosum group A (搜索) (Shoji et al., 2025; Okur et al., 2020; Okur et al., 2020; Fang et al., 2014). The company notes that these studies were not conducted with NB4168 and were not registrational, but they support the rationale for advancing NB4168 in rare pediatric diseases.
"The NB4168 (搜索) program is focused and stage-gated: a proprietary molecule, a rare pediatric disease with high unmet need, a mechanistic link to NAD+ biology, and measurable pharmacokinetic and pharmacodynamic endpoints," said Andrew Shao, Ph.D., Senior Vice President, Global Scientific & Regulatory Affairs. "Our objective is to generate the pharmacological, toxicological, and eventually clinical evidence needed to determine whether NB4168 can provide meaningful benefit to patients."
Strategic Expansion into Regulated Drug Development
The launch of NB4168 (搜索) represents a significant evolution for Niagen Bioscience (搜索), which has built its reputation on NAD+ science and healthy aging research through its consumer product portfolio — including its flagship patented NR ingredient Niagen, Tru Niagen, and Niagen Plus. The company maintains a portfolio of over 50 patents protecting NR and other NAD+ precursors. With NB4168, the company now aims to translate its NAD+ platform into therapies for accelerated aging and rare genetic diseases where DNA misrepair and mitochondrial dysfunction are foundational underlying causes.